RNA Polymerase Inhibitors with Activity against Rifampin-Resistant Mutants of Staphylococcus aureus
AUTOR(ES)
O'Neill, Alexander
FONTE
American Society for Microbiology
RESUMO
A collection of rifampin-resistant mutants of Staphylococcus aureus with characterized RNA polymerase β-subunit (rpoB) gene mutations was cross-screened against a number of other RNA polymerase inhibitors to correlate susceptibility with specific rpoB genotypes. The rpoB mutants were cross-resistant to streptolydigin and sorangicin A. In contrast, thiolutin, holomycin, corallopyronin A, and ripostatin A retained activity against the rpoB mutants. The second group of inhibitors may be of interest as drug development candidates.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=101622Documentos Relacionados
- Rifampin-Resistant RNA Polymerase Mutants of Chlamydia trachomatis Remain Susceptible to the Ansamycin Rifalazil
- Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus.
- Rifampin-resistant mutants of Myxococcus xanthus defective in development.
- Emergence of rifampin-resistant Haemophilus influenzae.
- Increased levels of dihydrofolate reductase in rifampin-resistant mutants of Bacillus subtilis.
